Ivabradine and Vericiguat in Heart Failure
On this page
Direct answer
Ivabradine slows the sinus node without touching blood pressure; vericiguat sensitises soluble guanylate cyclase to nitric oxide without relying on PDE5 — two different attacks on the failing heart's physiology. Ivabradine blocks the If (HCN4) current, and SHIFT showed an 18 per cent reduction in cardiovascular death or heart failure hospitalisation in HFrEF patients in sinus rhythm with heart rate at or above 70 despite maximised beta-blocker; dose 2.5-7.5 mg twice daily, limited by bradycardia and luminous phosphenes. Vericiguat, started at 2.5 mg daily and titrated to 10 mg, delivered the VICTORIA trial's 10 per cent reduction in death or heart failure hospitalisation in patients with recent worsening heart failure; both drugs must never ride in the same sentence as nitrates or PDE5 inhibitors — vericiguat because of hypotension, and neither is an angina or potency drug.
What you must remember
- Ivabradine identity: selective If channel (HCN) blocker in the sinoatrial node — pure heart-rate reduction, no negative inotropy, no blood pressure fall.
- SHIFT trial: sinus rhythm, heart rate 70 or above, on maximally tolerated beta-blocker — 18 per cent reduction in the primary composite, driven by heart failure hospitalisation.
- Ivabradine dosing: 5 mg twice daily starting (2.5 mg in the elderly), titrated to 7.5 mg twice daily; target resting rate around 55-60.
- The atrial fibrillation rule: ivabradine is useless in AF — it acts only on the sinus node; AF rate control needs AV-nodal drugs.
- Signature adverse effect: luminous phosphenes (retinal HCN channel effects) — transient, usually benign, driving rarely affected.
- Vericiguat identity: haem-dependent soluble guanylate cyclase stimulator — amplifies nitric oxide signalling to cyclic GMP; distinct from PDE5 inhibitors which prevent cGMP breakdown.
- VICTORIA: worsening heart failure within months (hospitalisation or IV diuretics); 2.5 mg daily with food, doubled every 2 weeks to 10 mg; about 10 per cent relative reduction in death or HF hospitalisation.
- Contraindications: vericiguat with nitrates, nitric oxide donors or PDE5 inhibitors (hypotension); ivabradine with strong CYP3A4 inhibitors and in resting bradycardia below 60.
Building the sequence for one patient
Walk a 58-year-old with an ejection fraction of 28 per cent, in sinus rhythm at 88 beats per minute on metoprolol succinate 100 mg (intolerant of more), eplerenone, dapagliflozin and sacubitril/valsartan. He was hospitalised for congestion six weeks ago. Two additions follow, in order of maturity. Ivabradine 5 mg twice daily now — his rate is above 70 in sinus rhythm despite maximised beta-blocker, the SHIFT population verbatim; retitrate by rate to 7.5 mg, expecting phosphenes in the first weeks, and re-verify rhythm annually because new atrial fibrillation silently converts the drug into a placebo. Vericiguat 2.5 mg daily with food at the same visit or soon after — VICTORIA's entry criterion (recent worsening) is met — doubling every two weeks toward 10 mg while systolic pressure stays above about 100. Neither replaces a guideline cornerstone; both are the fifth and sixth layers that recent trials added to the four-pillar foundation.
The physiological logic is exam-worthy: faster hearts worsen failure (shortened diastole, higher oxygen demand), while deficient nitric oxide-cGMP signalling drives myocardial and vascular stiffness — each drug repairs one axis the standard quadruple therapy does not.
Where students confuse the pair
Three confusions recur. First, ivabradine in atrial fibrillation — a favourite negative question; the answer is that AV nodal conduction, not sinus node If current, sets the ventricular rate in AF, so the drug has no target. Second, vericiguat versus riociguat versus sildenafil: riociguat is the sGC stimulator for pulmonary hypertension and chronic thromboembolic disease (dosage and indication differ), vericiguat the once-daily HFrEF agent, sildenafil the PDE5 inhibitor absolutely avoided with either stimulator — a three-way matching question in the making. Third, the nitrate rule: vericiguat cannot be combined with nitrates, which forces a genuine prescribing choice in the anginal heart failure patient. Indian reality: ivabradine is inexpensive and over-used at times as a beta-blocker substitute — it is not, having no mortality benefit — while vericiguat is the newer, costlier arrival; the exam expects SHIFT's 18 per cent and VICTORIA's 10 per cent, and the sinus-rhythm condition, as the quotable core.
Frequently asked questions
What is ivabradine's mechanism and why does it fail in atrial fibrillation?
It blocks the If current in the sinoatrial node; in AF the ventricular rate depends on AV nodal conduction, so ivabradine has no effect.
What were the SHIFT trial's entry criteria and result?
Sinus rhythm with heart rate 70 or above on maximally tolerated beta-blocker in HFrEF; ivabradine reduced cardiovascular death or heart failure hospitalisation by 18 per cent.
How is vericiguat dosed?
Start 2.5 mg once daily with food and up-titrate by doubling every two weeks to the 10 mg target.
Which drugs must not be combined with vericiguat?
Nitrates, nitric oxide donors and PDE5 inhibitors, because of cumulative hypotension from shared cyclic GMP pathways.
What are phosphenes on ivabradine?
Transient flashes or halos from retinal HCN channel blockade, typically resolving with continued therapy or dose reduction.